Showing 1–12 of 239 resultsSorted by latest
Healthcare
CrispIdea’s Healthcare Equity Reports provide in-depth analysis of key subsectors, including Pharma & Biotech, Medical Devices & Equipements, Health Care Plans and HCIT. Our insightful analysis covers stock ratings and recommendations, target price, investment thesis, peer comparisons, financial performance evaluations with valuation and ratio analysis, and management commentary. Stay ahead with CrispIdea, your trusted resource for informed investment decisions in the rapidly evolving healthcare landscape.
Intuitive successfully expanded its addressable market through platform diversification beyond traditional multiport surgery. The Ion endoluminal system achieved 52%
year-over-year procedure growth, reaching approximately 37,900 procedures in Q3FY25 with an installed base of approximately 954 systems.
Abbott’s product innovation trajectory demonstrates balanced pipeline construction with combination of iterative and transformative innovation, generating approximately $500 million in sales from recently launched products in Q3FY25 alone, contributing 100+bps to organic sales growth
Johnson & Johnson’s MedTech segment is entering a period of accelerated growth, driven by strong execution across its highest-potential categories. Cardiovascular, Robotics, and Vision. In Q3FY25, MedTech delivered 5.6% operational sales growth, marking one of its strongest quarters in recent years and reflecting broad momentum rather than isolated product outperformance.
UnitedHealth experienced above-trend growth in non-medical operating expenses, reflecting a combination of structural investment and inflationary overhead. The operating cost ratio reached 13.5% in Q3FY25, compared to 13.2% the previous year, despite company-wide efficiency programs.
Agilent paid $71mn in cash dividends during Q3FY25. This represented a dividend of $0.248 per common share. During the same period, the company repurchased and retired 737,474 shares of its common stock for $85mn. These repurchases were executed under the 2023 repurchase program. This represents that Agilent Technologies is committed in returning to its shareholders.
The massive multi year migration of Veeva’s core CRM business from the Salesforce Platform to its proprietary Veeva Vault platform, which is expected to peak in FY26 and FY27, comes with operational risk. This migration can cause potential business disruptions for
customers which may lead to the loss of customers to competitors.
Medtronic successfully reduced full year net tariff impact estimate from $200-350mn range to approximately $185mn through proactive supply chain optimization, production shifts across global manufacturing footprint and strategic sourcing adjustments.
Novartis’s immunology segment exhibits emerging momentum from regulatory approvals and Phase III readouts that signal revenue contribution potential beginning 2025-2026 and extending through 2029, creating medium-term earnings visibility independent of mature product deterioration
BD has announced that it will combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust structure, with a total value of $17.5bn.
RP Management’s internalization in May 2025 was a transformational milestone that will deliver over $100mn in annual cash savings to the company in 2026 alone, and exceed $175mn by 2030, totalling over $1.6bn over the next ten years.
Teva’s “Transforming Teva” program is targeting net annual savings of $700mn by 2027, with two-thirds planned to be achieved by the end of 2026. As of Q2FY25, the company has already achieved 20% run-rate savings. The program has three pillars, i.e. 8% workforce reduction focused on middle management and support roles, digital and AI based modernization in finance and HR, and 10% external spend optimization through vendor consolidation and procurement efficiency.
The main driver of ADMA’s growth is ASCENIV, a specialized IVIG that contains high-titer antibodies against RSV. Both product utilization and new patient starts are accelerating, indicating strong demand momentum.